Physician profile
Padmini Thakkar
NPI 1467461863
$1,760.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $324 · 2021: $505.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $363.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $342.75 | 2019-2021 | |
| Amarin Pharma, INC. | $254.32 | 2019-2021 | |
| Novo Nordisk INC | $212.38 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.10 | 2019-2021 | |
| Vertiflex, INC. | $109.86 | 2019 | |
| Pfizer INC. | $104.29 | 2020-2021 | |
| Glaxosmithkline, LLC. | $86.70 | 2020-2021 | |
| Esperion Therapeutics, INC. | $38.65 | 2020-2021 | |
| Astellas Pharma US INC | $30.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.98 | 2021 | |
| Allergan, INC. | $12.61 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmini Thakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.